Immix Biopharma, Inc.
IMMXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the. With a market capitalization of $675.7M, it sits in small-cap territory. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Market Cap
$675.7M
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
-8.60
EPS (TTM)
$-0.86
EPS (Fwd)
$-0.95
ROE
-34.2%
ROA
-20.5%
Cash
$232.1M
Total Debt
$1.0M
Free CF
-$25.4M
52W Change
125.8%
Annual Financials
Cash vs Debt
Where IMMX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMMX finished 18.85% below its 150-day moving average ($10.13) and 11.90% below its 200-day moving average ($9.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMMX overbought or oversold?
At the October 20, 2026 close, IMMX's RSI(14) was 23.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $232.1M in cash and $1.0M in debt, IMMX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$25.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -34.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.24 suggests IMMX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, IMMX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMMX.